Akebia Therapeutics, Inc. (AKBA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1149959,
    "name": "Akebia Therapeutics, Inc.",
    "stock_name": "Akebia Therapeutics, Inc.",
    "full_name": "Akebia Therapeutics, Inc.",
    "name_url": "stocks-analysis/akebia-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.59",
    "chg": 0.12,
    "chgp": "8.16%",
    "dir": 1,
    "prev_price": "1.47",
    "mcapval": "829.90",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US00972D1054",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "868.46 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/akebia-therapeutics-inc-1149959-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Akebia Therapeutics Hits New 52-Week Low at $1.49",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/akebia-therapeutics-hits-new-52-week-low-at-149-3726080",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AkebiaTherapeut_priceRelatedfactors_3726080.png",
        "date": "2025-11-24 16:21:09",
        "description": "Akebia Therapeutics, Inc. has reached a new 52-week low, reflecting ongoing challenges in a competitive market. The company has reported a decline in net sales and negative return on equity, despite achieving a recent quarterly sales high. Institutional holdings remain significant, indicating some investor confidence amid financial difficulties."
      },
      {
        "title": "Akebia Therapeutics Hits Day Low of $2.08 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/akebia-therapeutics-hits-day-low-of-208-amid-price-pressure-3659291",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AkebiaTherapeut_priceRelatedfactors_3659291.png",
        "date": "2025-10-30 19:24:57",
        "description": "Akebia Therapeutics, Inc. has faced significant stock volatility, dropping sharply today and over the past week. Despite recent challenges, the company reported strong quarterly net sales and has outperformed the S&P 500 over the past year and three years, indicating resilience in a competitive market."
      },
      {
        "title": "Akebia Therapeutics Achieves Multibagger Status with 123.31% Stock Increase Over Past Year",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/akebia-therapeutics-achieves-multibagger-status-with-12331-stock-increase-over-past-year-3600760",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AkebiaTherapeut_multibagger_3600760.png",
        "date": "2025-10-07 19:04:33",
        "description": "Akebia Therapeutics, Inc. has recently undergone a revision in its stock evaluation, reflecting its strong performance metrics. The company has achieved impressive returns over various timeframes, significantly outpacing the S&P 500. Despite facing challenges, Akebia's recent positive results and reduced costs indicate a promising outlook for investors."
      },
      {
        "title": "Is Akebia Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-akebia-therapeutics-inc-technically-bullish-or-bearish-3546810",
        "imagepath": "",
        "date": "2025-09-20 19:40:56",
        "description": "As of 7 August 2025, the technical trend for Akebia Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The Bollinger Bands show a mixed signal with weekly mildly bearish and monthly mildly bullish readings. Overall, while the stock has significantly outperformed the S&P 500 over the past year (119.26% vs. 17.14%), recent short-term performance has lagged, with a 1-week return of -1.00% compared to the S&P 500's 1.05%...."
      },
      {
        "title": "Is Akebia Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-akebia-therapeutics-inc-overvalued-or-undervalued-3543308",
        "imagepath": "",
        "date": "2025-09-20 18:16:04",
        "description": "As of 6 March 2017, the valuation grade for Akebia Therapeutics, Inc. moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its high Price to Book Value of 42.42 and negative EV to EBIT of -51.46, alongside a troubling ROE of -184.16%. In comparison, peers such as Y-mAbs Therapeutics, Inc. have a lower EV to EBITDA of -12.49, and scPharmaceuticals, Inc. shows a more favorable EV to Sales ratio of -4.64, highlighting Akebia's relative weakness in valuation metrics.\n\nDespite a strong year-to-date return of 55.79% compared to the S&P 500's 12.22%, the overall valuation ratios suggest that Akebia is not positioned favorably within its industry. The combination of high valuation ratios and negative returns on equity supports the conclusion that Akebia Therapeutics, Inc. is overvalued...."
      }
    ],
    "total": 10,
    "sid": "1149959",
    "stock_news_url": "https://www.marketsmojo.com/news/akebia-therapeutics-inc-1149959"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Akebia Therapeutics Hits New 52-Week Low at $1.49

2025-11-24 16:21:09

Akebia Therapeutics, Inc. has reached a new 52-week low, reflecting ongoing challenges in a competitive market. The company has reported a decline in net sales and negative return on equity, despite achieving a recent quarterly sales high. Institutional holdings remain significant, indicating some investor confidence amid financial difficulties.

Akebia Therapeutics Hits Day Low of $2.08 Amid Price Pressure

2025-10-30 19:24:57

Akebia Therapeutics, Inc. has faced significant stock volatility, dropping sharply today and over the past week. Despite recent challenges, the company reported strong quarterly net sales and has outperformed the S&P 500 over the past year and three years, indicating resilience in a competitive market.

Akebia Therapeutics Achieves Multibagger Status with 123.31% Stock Increase Over Past Year

2025-10-07 19:04:33

Akebia Therapeutics, Inc. has recently undergone a revision in its stock evaluation, reflecting its strong performance metrics. The company has achieved impressive returns over various timeframes, significantly outpacing the S&P 500. Despite facing challenges, Akebia's recent positive results and reduced costs indicate a promising outlook for investors.

Is Akebia Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:40:56

As of 7 August 2025, the technical trend for Akebia Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The Bollinger Bands show a mixed signal with weekly mildly bearish and monthly mildly bullish readings. Overall, while the stock has significantly outperformed the S&P 500 over the past year (119.26% vs. 17.14%), recent short-term performance has lagged, with a 1-week return of -1.00% compared to the S&P 500's 1.05%....

Is Akebia Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:16:04

As of 6 March 2017, the valuation grade for Akebia Therapeutics, Inc. moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its high Price to Book Value of 42.42 and negative EV to EBIT of -51.46, alongside a troubling ROE of -184.16%. In comparison, peers such as Y-mAbs Therapeutics, Inc. have a lower EV to EBITDA of -12.49, and scPharmaceuticals, Inc. shows a more favorable EV to Sales ratio of -4.64, highlighting Akebia's relative weakness in valuation metrics. Despite a strong year-to-date return of 55.79% compared to the S&P 500's 12.22%, the overall valuation ratios suggest that Akebia is not positioned favorably within its industry. The combination of high valuation ratios and negative returns on equity supports the conclusion that Akebia Therapeutics, Inc. is overvalued....

View All News